Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come

Executive Summary

It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses

You may also be interested in...



NICE Price: Zytiga On Track In England After Discount

Janssen’s decision to offer the NHS a discount for its oral prostate cancer treatment Zytiga appears to have paid off, giving the drug a boost and head start over potential rivals in the EU.

NICE Rules Out Sanofi’s Jevtana On Grounds Of Cost Effectiveness

NICE has turned down Sanofi’s Jevtana for prostate cancer, raising fears in England of a new post-code lottery for cancer drugs and highlighting the different between Germany and England’s health technology assessments.

European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth

It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel